Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.14.14.1: unspecific monooxygenase

This is an abbreviated version!
For detailed information about unspecific monooxygenase, go to the full flat file.

Word Map on EC 1.14.14.1

Reaction

RH
+
[reduced NADPH-hemoprotein reductase]
 +
O2
=
ROH
 +
[oxidized NADPH-hemoprotein reductase]
 +
H2O

Synonyms

3AH15, 6 beta-hydroxylase, 6-beta-testosterone hydroxylase, 7-alkoxycoumarin O-dealkylase, 7-ethoxycoumarin-O-deethylase, 7-ethoxyresorufin-O-deethylase, AA omega-hydroxylase, Aldehyde oxygenase, Arachidonic acid epoxygenase, aromatase, aryl hydrocarbon hydroxylase, aryl-4-monooxygenase, BG04_163, BM3, BPH, Brain aromatase, class IV cytochrome P450 monooxygenase, clavine oxidase, CLOA, Clone PF26, Clone PF3/46, Coumarin 7-hydroxylase, CP2D6, Cyp, CYP monooxygenase, CYP102, CYP102 monooxygenase, CYP1027H1, CYP102A1, CYP102A2, CYP102A3, CYP102A7, CYP102B1, CYP106, CYP107, CYP1074A2, CYP109, CYP116B3, CYP116B4, CYP116B46, CYP134, CYP150A20, CYP152, CYP154H1, CYP19, CYP197, CYP1A, CYP1A1, CYP1A2, CYP1A3, CYP1B1, CYP24A1, CYP27A1, CYP28A5, CYP2A3, CYP2A6, CYP2B, CYP2B4, CYP2B6, CYP2C11, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP305A1, CYP3A, CYP3A1, CYP3A4, CYP3A5, CYP3A7, CYP4, CYP4502F4, CYP4A, CYP4A4, CYP4A6, CYP4A7, CYP4AA1, CYP4E2, CYP4F, CYP4F2, CYP4F3A, CYP4F3B, CYP5035A2, CYP5035A3, CYP5035A5, CYP5035C1, CYP5036A1, CYP5036A3, CYP5037B2, CYP505D1, CYP505D2, CYP505D3, CYP505D4, CYP51, CYP512B5, CYP512H1, CYP5136A2, CYP5136A3, CYP5136A5, CYP5139A1, CYP5141A1, CYP5141D1, CYP5142A3, CYP5142C1, CYP5144A3, CYP5144A7, CYP5144A9, CYP5144C7, CYP5144D4, CYP5145A3, CYP5147A1, CYP5150B1, CYP53A15, CYP53C2, CYP53D2, CYP5A1, CYP63A2, CYP6B1, CYP6B1v1, CYP6B1V1/CYP6B1V2/ CYP6B1V3, CYP6B3V1/CYP6B3V2, CYP6B4V1/CYP6B4V2, CYP6B5V1, CYP714D1, CYP82E2, CYP82E3, CYP82E4v1, CYP82E4v2, CYP8A1, CYP9F2, CYPIA1, CYPIA2, CYPIA4, CYPIA5, CYPIB1, CYPIIA1, CYPIIA10, CYPIIA11, CYPIIA12, CYPIIA13, CYPIIA2, CYPIIA3, CYPIIA4, CYPIIA5, CYPIIA6, CYPIIA7, CYPIIA8, CYPIIA9, CYPIIB1, CYPIIB10, CYPIIB11, CYPIIB12, CYPIIB19, CYPIIB2, CYPIIB20, CYPIIB3, CYPIIB4, CYPIIB5, CYPIIB6, CYPIIB9, CYPIIC1, CYPIIC10, CYPIIC11, CYPIIC12, CYPIIC13, CYPIIC14, CYPIIC15, CYPIIC16, CYPIIC17, CYPIIC18, CYPIIC19, CYPIIC2, CYPIIC20, CYPIIC21, CYPIIC22, CYPIIC23, CYPIIC24, CYPIIC25, CYPIIC26, CYPIIC27, CYPIIC28, CYPIIC29, CYPIIC3, CYPIIC30, CYPIIC31, CYPIIC37, CYPIIC38, CYPIIC39, CYPIIC4, CYPIIC40, CYPIIC41, CYPIIC42, CYPIIC5, CYPIIC6, CYPIIC7, CYPIIC8, CYPIIC9, CYPIID1, CYPIID10, CYPIID11, CYPIID14, CYPIID15, CYPIID16, CYPIID17, CYPIID18, CYPIID19, CYPIID2, CYPIID3, CYPIID4, CYPIID5, CYPIID6, CYPIID9, CYPIIE1, CYPIIF1, CYPIIF3, CYPIIF4, CYPIIG1, CYPIIH1, CYPIIH2, CYPIIIA1, CYPIIIA10, CYPIIIA11, CYPIIIA12, CYPIIIA13, CYPIIIA14, CYPIIIA15, CYPIIIA16, CYPIIIA17, CYPIIIA18, CYPIIIA19, CYPIIIA2, CYPIIIA21, CYPIIIA24, CYPIIIA25, CYPIIIA27, CYPIIIA28, CYPIIIA29, CYPIIIA3, CYPIIIA30, CYPIIIA31, CYPIIIA5, CYPIIIA6, CYPIIIA7, CYPIIIA8, CYPIIIA9, CYPIIJ1, CYPIIJ2, CYPIIJ3, CYPIIJ5, CYPIIJ6, CYPIIK1, CYPIIK3, CYPIIK4, CYPIIL1, CYPIIM1, CYPIVA4, CYPIVA8, CYPIVB1, CYPIVC1, CYPIVF1, CYPIVF11, CYPIVF12, CYPIVF4, CYPIVF5, CYPIVF6, CYPIVF8, CYPVIA1, CYPVIB1, CYPVIB2, CYPVIB4, CYPVIB5, CYPVIB6, CYPVIB7, CYPXIX, CYPXIXA1, CYPXIXA2, CYPXIXA3, Cyt P450, cytochrome P-450 4 enzyme, cytochrome P-450 BM3, cytochrome P-450 monooxygenase, cytochrome P450 2B4, cytochrome P450 3A, cytochrome P450 3A4, cytochrome P450 aromatase, cytochrome P450 BM3, cytochrome P450 monooxygenase, cytochrome P450 monooxygenase 116B3, cytochrome P450 monooxygenase 2A6, cytochrome P450 monooxygenase 2C8, cytochrome P450 monooxygenase 2C9, cytochrome P450 monooxygenase 3A4, cytochrome P450 monooxygenase pc-2, cytochrome P450 monooxygenase pc-4, cytochrome P450 monooxygenase pc-5, cytochrome P450 monooxygenase pc-6, cytochrome P450 monooxygenase PC-foxy1, cytochrome P450 oxidoreductase, cytochrome P450 reductase, Cytochrome P450-D2, cytochrome P450-dependent monooxygenase, cytochrome P450-dependent monooxygenase 1A2, cytochrome P450-monooxygenase, cytochrome-P450 hydroxylase, DAH1, DAH2, Debrisoquine 4-hydroxylase, EC 1.14.1.1, EC 1.14.14.2, EC 1.14.99.8, EC 1.99.1.1, ECOD, Ema, EROD, Estrogen synthetase, EUI, fatty acid hydroxylase, flavocytochrome P450BM-3, flavoprotein monooxygenase, flavoprotein-linked monooxygenase, FMO3, FraEuI1c_1415, FraEuI1c_2494, FraEuI1c_5334, GA 16a,17-epoxidase, GA-deactivating enzyme, Hepatic cytochrome P-450MC1, HLp, HMPREF1624_01477, IIA3, Isozyme 3A, Laurate omega-1 hydroxylase, Lauric acid omega-6-hydroxylase, liver cytochrome P450-dependent monooxygenase, LMC1, Mephenytoin 4-hydroxylase, MFO, microsomal monooxygenase, microsomal P-450, mixed function oxygenase, monooxygenase 3, monooxygenase P450 BM-3, More, N-demethylase, nicotine oxidase, O-demethylase, OLF2, Olfactive, Os05g0482400 protein, Ovarian aromatase, oxygenase, flavoprotein-linked mono-, P(3)450, P-448, P-450 PHPAH1, P-450(M-1), P-450-MK2, P-450AROM, P-450IB, P-450IIIAM1, P-450MC, P-450MP, P-450UT, P1-88, P24, P450, P450 17-alpha, P450 19A1, P450 1A1, P450 1A2, P450 1B1, P450 2A6, P450 2B6, P450 2C19, P450 2C9, P450 2D-29/2D-35, P450 2D6, P450 2E1, P450 2J2, P450 3A4, P450 4A11, P450 4F2, P450 BM3, P450 CM3A-10, P450 DUT2, P450 FA, P450 FI, P450 form 3B, P450 form HP1, P450 HSM1, P450 HSM2, P450 HSM3, P450 HSM4, P450 IIB1, P450 IIC2, P450 LM4, P450 LM6, P450 LMC2, P450 MD, P450 monooxygenase, P450 MP-12/MP-20, P450 P49, P450 PB1, P450 PB4, P450 PBC1, P450 PBC2, P450 PBC3, P450 PBC4, P450 PCHP3, P450 PCHP7, P450 TCDDAA, P450 TCDDAHH, P450 type B2, P450 types B0 and B1, P450(I), P450-11A, P450-15-alpha, P450-15-COH, P450-16-alpha, P450-254C, P450-3C, P450-6B/29C, P450-A3, P450-AFB, P450-ALC, P450-BM3, P450-CMF1A, P450-CMF1B, P450-CMF2, P450-CMF3, P450-DB1, P450-DB2, P450-DB3, P450-DB4, P450-DB5, P450-HFLA, P450-HP, P450-IIA10, P450-IIA11, P450-IIA3.1, P450-IIA3.2, P450-IIA4, P450-KP1, P450-LM2, P450-MC1, P450-MC4, P450-MK1, P450-MKJ1, P450-MKMP13, P450-MKNF2, P450-NMB, P450-OLF1, P450-OLF3, P450-P1, P450-P2/P450-P3, P450-P3, P450-PB1 and P450-PB2, P450-PCN1, P450-PCN2, P450-PCN3, P450-PM4, P450-PP1, P450-PROS2, P4501A1, P450arom, P450cam, P450CB, P450CMEF, P450E, P450EF, P450F, P450H, P450I, P450IIC5, P450MT2, P450RAP, P450RLM6, P450s 3A, P450SMO, P52, PB15, PHP2, PHP3, PikC, PikC hydroxylase, Progesterone 21-hydroxylase, Prostaglandin omega-hydroxylase, PTF1, PTF2, S-mephenytoin 4-hydroxylase, Sam5, sertraline N-demethylase, SIAM614_30676, Steroid hormones 7-alpha-hydroxylase, Testosterone 15-alpha-hydroxylase, Testosterone 16-alpha hydroxylase, Testosterone 6-beta-hydroxylase, Testosterone 7-alpha-hydroxylase, xenobiotic monooxygenase

ECTree

     1 Oxidoreductases
         1.14 Acting on paired donors, with incorporation or reduction of molecular oxygen
             1.14.14 With reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen into the other donor
                1.14.14.1 unspecific monooxygenase

Inhibitors

Inhibitors on EC 1.14.14.1 - unspecific monooxygenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1-aminobenzotriazole
-
moderately prohibits spontaneous mutations of V79-hCYP2E1-hSULT1A1 cells. In combination with SULT1A1 inhibitor pentachlorophenol completely prohibits spontaneous mutations of V79-hCYP2E1-hSULT1A1 cells
17alpha-ethynylestradiol
-
reactive intermediates of 17alpha-ethynylestradiol inactivate P450s in a NADPH-dependent mechanism-based manner by a combination of heme alkylation and apoprotein modification
8-methoxypsoralen
-
-
anastrozole
-
profiling inhibition of probe 1 labeling of P450 19A1, inhibits labeling of P450 2C9 by probe 5
Atrazine
bifonazole
bitertanol
-
7-ethoxyresorufin O-deethylation is inhibited by the fungicide bitertanol, IC50: 800-900 nM
chlorotoluron
cimetidine
-
specific inhibition
diethyldithiocarbamate
CYP2E1
dimethyl sulfoxide
-
CYP102A7 exhibits 50% of its initial activity in the presence of 26% dimethyl sulfoxide
Diuron
Emulgen
-
a detergent that inactivates the enzyme at high concentrations
-
erdafitinib
fibroblast growth factor receptor inhibitor, irreversible covalent mechanism-based inhibitor of both isoforms CYP3A4 and CYP3A5; fibroblast growth factor receptor inhibitor, irreversible covalent mechanism-based inhibitor of both isoforms CYP3A4 and CYP3A5
-
formestane
-
profiling inhibition of probe 1 labeling of P450 19A1, decreases probe 5 labeling of P450 2C19 and 1 labeling of P450 3A4
furafylline
H2O2
-
at high concentrations
imidazole
-
at 20 mM, only half of P450SMO activity remains
ketoconazole
methanol
partially affects (10-20%) activity of the active recombinant enzyme; partially affects (10-20%) activity of the active recombinant enzyme; partially affects (10-20%) activity of the active recombinant enzyme; partially affects (10-20%) activity of the active recombinant enzyme; partially affects (10-20%) activity of the active recombinant enzyme; partially affects (10-20%) activity of the active recombinant enzymes
N-benzoloxycarbonyl-Leu-Leu-leucinal
-
MG132, high concentrations are cytotoxic and can suppress CYP3A synthesis. Biphasic concentration effect on CYP3A turnover: stabilization at 0.005 to 0.01 mM with marked suppression at more than 0.1 mM. Marked (approximately 4fold) MG132 concentration-dependent RNA-dependent protein kinase-like ER-bound elF2alpha-kinase autophosphorylation, along with an 8fold increase in elF2alpha-phosphorylation. In parallel, MG132 also activates general control nonderepressible-2 elF2alpha kinase in a concentration-dependent manner, but not the heme-regulated inhibitor elF2alpha kinase. Consequently dramatic translational shutoff of total hepatic protein, including but not limited to CYP3A and tryptophan 2,3-dioxygenase protein syntheses
piperonyl butoxide
sorafenib N-oxide
both sorafenib and sorafenib N-oxide interacts with active site residues in CYP2C8, but four additional major hydrogen and halogen bonding interactions are identified between sorafenib N-oxide and amino acids in the B-B' loop region and helixes F' and I of the the catalytic region
-
sulfaphenazole
ticlopidine
CYP2B6 and CYP2C19, 40% loss of sulfoxide formation. Decrease in fenthion-oxon formation by 71% and 64% at 0.005 mM or 0.1 mM fenthion concentrations, respectively, which is mainly attributable to CYP2B6
tranylcypromine
CYP2C19
additional information
-